An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Tepezza

Chemical Nameteprotumumab-trbw
Dosage FormInjectable (intravenous; 500 mg/vial)
Drug ClassMonoclonal antibodies
SystemEndocrine
CompanyHorizon Therapeutics Ireland
Approval Year2020

Indication

  • Tepezza is indicated for the treatment of Thyroid Eye Disease.
Last updated on 11/10/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tepezza (teprotumumab-trbw) Prescribing Information2020Horizon Therapeutics Ireland
Document TitleYearSource
Teprotumumab for the treatment of active thyroid eye disease2020The New England Journal of Medicine